Ascend Wellness Holdings (AAWH) Restructuring Costs (2021 - 2022)
Ascend Wellness Holdings' (AAWH) quarterly Restructuring Costs came in at $5.0 million in Q1 2022, down 86.31% year-on-year from $36.5 million in Q1 2021, and down 86.31% quarter-over-quarter from $36.5 million in Q1 2021.
Ascend Wellness Holdings (AAWH) Restructuring Costs (2021 - 2022) Analysis & Trends
Ascend Wellness Holdings' Restructuring Costs history runs 2 years deep, the most recent figure standing at $5.0 million for Q1 2022.
- On a quarterly basis, Restructuring Costs fell 86.31% year-over-year to $5.0 million in Q1 2022; TTM through Dec 2022 was $5.0 million, a 86.31% decrease from a year earlier, with the FY2025 full-year figure at $17.0 million, changed N/A from the prior year.
- Restructuring Costs declined to $5.0 million in Q1 2022 per AAWH's latest filing, from $36.5 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $36.5 million in Q1 2021 and bottomed at $5.0 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Ascend Wellness Holdings | 83.00 Mn | 22.91 Mn | 44.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 5.00 Mn |
| Mar 31, 2021 | 36.51 Mn |